Drug

Mecamylamine

In clinical development

ClassNeuronal acetylcholine receptor; alpha4/beta2 antagonistEmerging researchLate-stage development

Also known as Inversine, Vecamyl.

RxNorm6673 ChEMBLCHEMBL2103881UNII6EE945D3OK

Research papers

Active clinical trials

Protein targets

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Treatment of Orthostatic Intolerance

Clinical trial2025-10-08Results expected Q4 2029 · ClinicalTrials.gov

Pilot Study of Mecamylamine for Autonomic Dysreflexia Prophylaxis

Clinical trial2020-03-17Primary completion · ClinicalTrials.gov

Nicotinic Modulation of the Default Network of Resting Brain Function

Clinical trial2019-08-19Results posted · ClinicalTrials.gov

Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients

Clinical trial2019-06-04Results posted · ClinicalTrials.gov

Cognitive Effects of Mecamylamine and Varenicline in Schizophrenia

Clinical trial2017-03-28Results posted · ClinicalTrials.gov

Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence

Clinical trial2016-04-18Results posted · ClinicalTrials.gov

Neuronal Nicotinic Receptor Modulation in the Treatment of Autism: A Pilot Trial of Mecamylamine

Clinical trial2012-11-01Completed · ClinicalTrials.gov

A Phase II Randomized, Double-Masked, Study Comparing the Safety and Efficacy of ATG003 in Patients With Neovascular ("Wet") Age-Related Macular Degeneration (NV-AMD)

Clinical trial2009-09-01Terminated · ClinicalTrials.gov

Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus.

Research2008-12-01The Journal of neuroscience : the official journal of the Society for Neuroscience

Phase 2 Study of the Safety and Bioactivity of Topical Ocular Mecamylamine for the Treatment of Diabetic Macular Edema (DME)

Clinical trial2008-04-01Completed · ClinicalTrials.gov

A Multi-Center, Double Blind, Randomized, Placebo-Controlled, Parallel Group, Flexible Dose Titration, Add-On Study of Mecamylamine 5.0 to 10 mg, in the Treatment of Major Depressive Disorder With Subjects Who Are Partial or Non- Responders to Citalopram Therapy.

Clinical trial2006-08-01Completed · ClinicalTrials.gov

Combinations of Pharmacologic Smoking Cessation Treatments

Clinical trial2001-06-01Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Mecamylamine

Aliases & brands

InversineVecamyl

RxNorm CUI

6673

ChEMBL ID

CHEMBL2103881

UNII

6EE945D3OK

Primary mechanism

Neuronal acetylcholine receptor; alpha4/beta2 antagonist

Pharmacology & targets

2 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Neuronal acetylcholine receptor subunit beta-2

CHRNB2 · P17787

ANTAGONISTNeuronal acetylcholine receptor; alpha4/beta2 antagonist

Neuronal acetylcholine receptor subunit alpha-4

CHRNA4 · P43681

ANTAGONISTNeuronal acetylcholine receptor; alpha4/beta2 antagonist

Clinical trials

12 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2015

Active studies

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 12

Phase 12Phase 1 / 21Phase 25Phase 31Phase 41Phase N / A2

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Pilot Study of Mecamylamine for Autonomic Dysreflexia Prophylaxis

Unknown statusPH IVWayne State Universityn=52020

Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence

CompletedPH IIIYale Universityn=212014

Recent completions

Trials that read out recently, adding to the completed evidence base.

Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients

CompletedPH IIYale Universityn=1362015

Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence

CompletedPH IIIYale Universityn=212014

Nicotinic Modulation of the Default Network of Resting Brain Function

CompletedN/AUniversity of Maryland, Baltimoren=212013

Cognitive Effects of Mecamylamine and Varenicline in Schizophrenia

CompletedN/AMassachusetts General Hospitaln=892013

Neuronal Nicotinic Receptor Modulation in the Treatment of Autism: A Pilot Trial of Mecamylamine

CompletedPH IOhio State Universityn=202012

Phase 2 Study of the Safety and Bioactivity of Topical Ocular Mecamylamine for the Treatment of Diabetic Macular Edema (DME)

CompletedPH IICoMentis2008

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus.

The Journal of neuroscience : the official journal of the Society for Neuroscience · 2008 · 580 cites